LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

Search

Quidel Corp

Abrir

27.38

Visão Geral

Variação de preço das ações

24h

Atual

Mín

26.96

Máximo

27.53

Indicadores-chave

By Trading Economics

Funcionários

6,600

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+25.82% upside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

5.6M

1.6B

Abertura anterior

27.38

Fecho anterior

27.38

Quidel Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

27 de nov. de 2025, 16:49 UTC

Aquisições, Fusões, Aquisições de Empresas

Deutsche Boerse in Talks to Buy Fund-Tech Platform Allfunds in $6 Billion Deal

27 de nov. de 2025, 15:32 UTC

Aquisições, Fusões, Aquisições de Empresas

TotalEnergies, Repsol in Talks to Combine U.K. North Sea Assets, Cinco Dias Says, Citing Sources

27 de nov. de 2025, 23:50 UTC

Conversa de Mercado

Nikkei May Trade Rangebound Amid Caution Over Economic Outlook -- Market Talk

27 de nov. de 2025, 23:50 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 de nov. de 2025, 16:05 UTC

Conversa de Mercado

Canadian Job Vacancies Rise for Fist Time Since Start of 2024 -- Market Talk

27 de nov. de 2025, 16:04 UTC

Conversa de Mercado

Canadian Payroll Employment Pulls Back in September, Offsetting Recent Gains -- Market Talk

27 de nov. de 2025, 15:54 UTC

Aquisições, Fusões, Aquisições de Empresas

Allfunds Shares Rise 21% After Deutsche Boerse Says Started Acquisition Talks

27 de nov. de 2025, 15:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Deutsche Boerse: No Certainty Talks Will Result in Transaction

27 de nov. de 2025, 15:43 UTC

Aquisições, Fusões, Aquisições de Empresas

Deutsche Boerse: Allfunds Board of Directors Has Agreed to Enter Exclusive Talks

27 de nov. de 2025, 15:42 UTC

Aquisições, Fusões, Aquisições de Empresas

Deutsche Boerse: Nonbinding Proposal is To Acquire Allfunds at EUR8.80 a Share

27 de nov. de 2025, 15:41 UTC

Aquisições, Fusões, Aquisições de Empresas

Deutsche Boerse in Talks With Allfunds on Possible Acquisition

27 de nov. de 2025, 15:11 UTC

Conversa de Mercado

Dollar Could Fall in 2026 as U.S. Rate Cuts Bite -- Market Talk

27 de nov. de 2025, 14:26 UTC

Conversa de Mercado

Hermes' Outperformance Gap Could Narrow -- Market Talk

27 de nov. de 2025, 14:11 UTC

Conversa de Mercado

Lack of Major Budget Surprises Don't Justify Continued Sterling Strength -- Market Talk

27 de nov. de 2025, 14:11 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

27 de nov. de 2025, 13:35 UTC

Conversa de Mercado

Richemont Looks Set to Continue Outgrowing Peers -- Market Talk

27 de nov. de 2025, 13:33 UTC

Conversa de Mercado

Sterling's Post-Budget Gains Are Probably Over -- Market Talk

27 de nov. de 2025, 13:22 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

27 de nov. de 2025, 13:22 UTC

Conversa de Mercado

Kering's Plan to Revive Gucci Needs More Clarity -- Market Talk

27 de nov. de 2025, 13:17 UTC

Conversa de Mercado

LVMH Should Be Able to Recover Next Year -- Market Talk

27 de nov. de 2025, 11:13 UTC

Conversa de Mercado

European Gas Prices Come Under Pressure -- Market Talk

27 de nov. de 2025, 11:07 UTC

Ganhos

Genting: Positive About Prospects Over Longer Term

27 de nov. de 2025, 11:06 UTC

Ganhos

Genting: Cautious on Near-Term Prospects of Leisure, Hospitality Industry

27 de nov. de 2025, 11:04 UTC

Ganhos

Genting: International Travel Demand Expected to Remain Resilient

27 de nov. de 2025, 11:04 UTC

Ganhos

Genting: Global Growth Expected to Remain Subdued

27 de nov. de 2025, 11:04 UTC

Ganhos

Genting: Ebitda Partly Weighed by Stronger Ringgit Vs. Singapore Dollar, British Pound, U.S. Dollar

27 de nov. de 2025, 10:59 UTC

Ganhos

Genting Bhd 3Q Net Profit Fell 86% on Year

27 de nov. de 2025, 10:58 UTC

Ganhos

Genting Bhd 3Q Rev Rose 14% on Year

27 de nov. de 2025, 10:56 UTC

Ganhos

Genting Bhd 3Q Net MYR30.3M

27 de nov. de 2025, 10:56 UTC

Ganhos

Genting Bhd 3Q EPS MYR0.0079

Comparação entre Pares

Variação de preço

Quidel Corp Previsão

Preço-alvo

By TipRanks

25.82% parte superior

Previsão para 12 meses

Média 34.6 USD  25.82%

Máximo 62 USD

Mínimo 22 USD

Com base em 7 analistas de Wall Street que oferecem metas de preço de 12 meses para Quidel Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

7 ratings

3

Comprar

3

Manter

1

Vender

Informação Financeira

$

Sobre Quidel Corp

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
help-icon Live chat